--- title: "Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3%" type: "News" locale: "en" url: "https://longbridge.com/en/news/280917464.md" description: "Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) experienced a 30.3% increase in short interest in March, totaling 8,417,915 shares. This represents approximately 12.7% of the company's stock being short sold, with a short-interest ratio of 6.5 days based on an average daily trading volume of 1,292,590 shares. The stock traded down to $2.83, with a market cap of $214.66 million. Analysts have a consensus rating of \"Hold\" for ELDN, with an average price target of $9.67. Institutional investors hold 56.77% of the stock, reflecting significant interest in the company." datetime: "2026-03-29T17:52:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280917464.md) - [en](https://longbridge.com/en/news/280917464.md) - [zh-HK](https://longbridge.com/zh-HK/news/280917464.md) --- # Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3% Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a significant growth in short interest in March. As of March 13th, there was short interest totaling 8,417,915 shares, a growth of 30.3% from the February 26th total of 6,458,931 shares. Approximately 12.7% of the company's stock are short sold. Based on an average daily volume of 1,292,590 shares, the short-interest ratio is currently 6.5 days. Get **Eledon Pharmaceuticals** alerts: ## Eledon Pharmaceuticals Stock Performance Shares of ELDN stock traded down $0.13 during trading on Friday, hitting $2.83. 864,502 shares of the company were exchanged, compared to its average volume of 1,556,412. The business's 50-day simple moving average is $2.44 and its 200 day simple moving average is $2.35. Eledon Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.60. The firm has a market capitalization of $214.66 million, a price-to-earnings ratio of -5.44 and a beta of 0.84. Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.10. On average, equities analysts forecast that Eledon Pharmaceuticals will post -0.81 earnings per share for the current fiscal year. ## Analyst Upgrades and Downgrades Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Eledon Pharmaceuticals in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $9.67. **Read Our Latest Stock Report on ELDN** ## Institutional Trading of Eledon Pharmaceuticals Several hedge funds and other institutional investors have recently modified their holdings of ELDN. Rockefeller Capital Management L.P. boosted its position in Eledon Pharmaceuticals by 95.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 71,666 shares of the company's stock valued at $108,000 after purchasing an additional 35,000 shares during the last quarter. Kera Capital Partners Inc. grew its position in Eledon Pharmaceuticals by 54.3% in the fourth quarter. Kera Capital Partners Inc. now owns 39,770 shares of the company's stock worth $60,000 after acquiring an additional 14,000 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Eledon Pharmaceuticals during the 4th quarter worth $39,000. XTX Topco Ltd increased its stake in shares of Eledon Pharmaceuticals by 867.1% during the 4th quarter. XTX Topco Ltd now owns 124,247 shares of the company's stock worth $188,000 after purchasing an additional 111,399 shares during the last quarter. Finally, Zimmer Partners LP raised its holdings in shares of Eledon Pharmaceuticals by 30.6% during the 4th quarter. Zimmer Partners LP now owns 2,384,228 shares of the company's stock valued at $3,600,000 after purchasing an additional 559,228 shares in the last quarter. 56.77% of the stock is currently owned by hedge funds and other institutional investors. ## About Eledon Pharmaceuticals (Get Free Report) Eledon Pharmaceuticals, Inc NASDAQ: ELDN is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders. Eledon's pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications. ## See Also - Five stocks we like better than Eledon Pharmaceuticals _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Eledon Pharmaceuticals Right Now? Before you consider Eledon Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list. While Eledon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md) - [Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort](https://longbridge.com/en/news/287276070.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [Vertex Says Health Canada Accepts Suzetrigine Application for Review](https://longbridge.com/en/news/287257602.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)